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124,63 kb, 8 Exon at least. 
Transcription 
The transcription of the RUNX2 gene is regulated by 
two different promoters. The larger P1 transcript gives 
rise to a protein starting with the amino acid sequence 
MASNS (Runx2-type II or OSF2/CBFA1a, 521 amino 
acids), whereas the P2 gives rise to a protein starting 
with MRIPV (Runx2-type I or isoform c, 507 amino 
acids). Transcript variants of this protein have been 
reported as well due to alternative splicing. 
Protein 
Description 
Runx2 is a transcription factor belonging to Runx 
family. This family is characterized by a highly 
conserved region of 128 amino acids, termed the Runt 
domain. The Runt domain is responsible for DNA 
binding and heterodimerization with CBFB (PEBP2b), 
which increases its DNA-binding affinity and also 
stabilizes RUNX proteins against proteolytic 
degradation. The C-terminal portion is rich in proline, 
serine and threonine (PST region) and contains 
functional domains acting to regulate transcription. 
Expression 
Runx2 expression is largely restricted to osteoblasts 
and mesenchymal condensations forming bones, 




Runx2 is an osteoblast-specific transcription factor that 
plays a central role in osteoblast differentiation, 
chondrocyte maturation, bone formation and 
remodeling. Moreover, it is a key target of mechanical 




Note: Heterozygous mutations (frameshift, nonsense, 
missense, splicing mutations) of the Runx2 gene have 
been identified in patients with Cleidocranial dysplasia 
(CCD). 
Implicated in 
Cleidocranial Dysplasia (CCD) 
Disease 
CCD is a dominantly inherited autosomal skeletal 
disorder that is characterized by open sutures and 
delayed closure of sutures, hypoplastic or aplastic 
clavicles, short stature, large fontanelles, dental 
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Prognosis 
CCD does not affect life expectancy and most 
diagnosed persons enjoy good overall health. There is 
no specific treatment for CCD and the dental problems 
are the most significant complications. 
Lymphomas 
Disease 
Runx2 and MYC collaborate in lymphoma 
development by suppressing apoptotic and growth 
arrest pathways in vivo. 
Multiple myeloma 
Disease 
Human myeloma cells express the bone regulating gene 
Runx2 and produce osteopontin that is involved in 
angiogenesis in multiple myeloma patients. 
Metastatic properties of cancer cells 
Disease 
Runx2 control multiple genes that contribute to the 
metastatic properties of cancer cells and their activity in 
the bone microenvironment. 
Breast cancer 
Disease 








Prostate cancer expression of runt-domain transcription 
factor Runx2. 
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